Shares of Eli Lilly (NYSE: LLY) rose approximately 4% on Monday following the release of encouraging clinical data for its next-generation obesity treatment, retatrutide. The positive results, presented at the American Diabetes Association's annual Scientific Sessions in New Orleans, have reinforced investor confidence in the company's long-term position within the rapidly expanding weight-loss market.
The latest data came from two late-stage studies involving treatment-naive type 2 diabetes patients and individuals living with obesity. Investors focused particularly on the performance of retatrutide's 4 mg dose, which delivered roughly 19% weight loss in clinical testing. According to analysts, this result is broadly comparable to the highest dose of Lilly's blockbuster obesity therapy Zepbound. The lower dose also demonstrated favorable tolerability, with relatively low treatment discontinuation rates and instances of vomiting, though side effects increased at higher doses.
Citi analysts noted in a research report that the 4 mg dose efficacy data for retatrutide are compelling enough that first-line positioning cannot be dismissed. They added that the treatment could become the next step for patients who have exhausted Lilly's tirzepatide efficacy. Lilly also highlighted additional findings showing that retatrutide produced meaningful improvements in knee osteoarthritis pain and sleep apnea alongside substantial weight loss.
The company further presented data on its oral obesity treatment Foundayo, previously known as orforglipron. Lilly said the pill was associated with significant weight loss in women across every stage of menopause, based on analyses from its Phase 3 ATTAIN-1 and ATTAIN-2 clinical trials. This breadth of pipeline development stood in contrast to rival Novo Nordisk, whose US-listed shares declined during the session despite announcing that prescriptions for its oral weight-loss therapy Wegovy had surpassed 3 million since its January launch.
Goldman Sachs analyst Asad Haider acknowledged Novo's early advantage after bringing oral Wegovy to market three months ahead of Lilly's Foundayo, describing it as one of the best pharmaceutical launches in recent history. However, Haider believes Lilly holds important long-term advantages, stating that Lilly is likely to continue dominating the GLP-1 market across both existing therapies and next-generation treatments. He added that it would be hard for Novo to scale over the years to meet international demand, whereas Lilly can.
Several analysts argued that Lilly's broader obesity portfolio gives it a growing competitive edge. J.P. Morgan analyst Chris Schott said that Lilly has the pieces in place to further raise the standard of care in the obesity space and sees the company extending its leadership position in the $200 billion+ incretin/obesity market longer term. Citi Research analyst Geoff Meacham maintained a positive outlook, noting that Lilly's incretin portfolio is not built around singular blockbusters, and that orforglipron and retatrutide carry development programs with enough indication breadth to make them category-defining franchises.
Meacham also highlighted Lilly's experimental obesity therapy eloralintide, saying the drug adds a genuinely differentiated layer to the company's portfolio, with Phase 2 data suggesting potentially best-in-class efficacy and tolerability. RBC Capital Markets analyst Trung Huynh echoed that view, stating that the depth of Lilly's obesity portfolio highlighted its leadership growing rather than a narrowing gap with competitors.
For broader market context, investors have also been watching other major movers such as Apple Stock Rises 1.6% Ahead of WWDC and MSTR Stock Rises 16% as Bitcoin Rally Pushes Holdings $1.8B Into Profit. Meanwhile, Sterling Rises to Three-Week High as geopolitical developments ease oil and inflation pressures.
This article is for informational purposes only and does not constitute financial advice.
